Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises

Area of Science:

• Oncology
• Molecular Biology
• Drug Delivery

Background:

• Prostate cancer (PCa) is a leading cause of cancer mortality in men, often driven by heterogeneous cancer stem cells (PCSCs) that confer treatment resistance.
• MicroRNA-34a (miR-34a) shows therapeutic potential against PCSCs by targeting key survival pathways, but its clinical application is limited by delivery challenges and toxicity.
• Ligand-mediated delivery, such as folate conjugation, aims to improve miR-34a specificity and reduce side effects, showing success in other cancer types.

Purpose of the Study:

• To investigate the efficacy and targeted delivery of folate-conjugated miR-34a (folate-miR-34a) in prostate cancer.
• To evaluate the expression of folate receptor alpha (FOLR1) and prostate-specific membrane antigen (PSMA) in PCa cells as potential targets for folate-miR-34a delivery.
• To understand the challenges and opportunities for developing ligand-conjugated miR-34a therapeutics for PCa.

Main Methods:

• Assessed miR-34a levels in PCa with TP53 alterations.
• Transfected PCa cells with miR-34a mimic to evaluate its effect on target gene expression and cell growth.
• Tested the anti-tumor efficacy and targeted delivery of folate-miR-34a in various cancer cell lines, including PCa, and analyzed FOLR1 and PSMA expression.

Main Results:

• miR-34a levels were reduced in PCa with TP53 loss or mutations; miR-34a mimic transfection inhibited PCa cell growth.
• Folate-miR-34a demonstrated significant anti-tumor effects in breast, ovarian, and cervical cancer cells.
• Folate-miR-34a showed minimal efficacy and targeted delivery in PCa cells, correlating with low FOLR1 expression and lack of folate binding to PSMA.

Conclusions:

• The therapeutic potential of folate-miR-34a for PCa is limited by the insufficient expression of target receptors like FOLR1 and PSMA on PCa cells.
• Targeted delivery strategies for miR-34a in PCa require alternative ligands or approaches that address the specific receptor landscape of prostate cancer.
• This study highlights critical challenges in developing ligand-conjugated miR-34a therapeutics for PCa, necessitating further research into novel delivery mechanisms.